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ABSTRACT 
A Nebulizer System for Positron Emission Tomography Imaging of Aerosols and Nanoparticles 
for Use in Preclinical Pulmonary Drug Delivery Studies 
  
 
Andrew Sterling Butters 
Department of Nuclear Engineering 
Texas A&M University 
 
Research Advisor: Dr. Gamal Akabani 
Department of Nuclear Engineering 
Texas A&M University 
 
 
 This research project proposes to develop, integrate and characterize a nebulizer system 
for the nasal pulmonary delivery of radiopharmaceuticals in the form of aerosols containing 
nanoparticles for dynamic imaging studies using positron emission tomography (PET) in small 
animal models of disease. PET imaging of inhaled radiolabeled drugs in the form of aerosols 
containing nanoparticles can provide an in vivo measurement of drug distribution using the drug 
itself as the tracer. The system will be composed of 1) a nebulizer generator, 2) an anesthesia 
system, 3) a gas exhaust system, 4) a physiological monitoring system for respiratory 
synchronization and nebulizer triggering, and 5) a cylindrical bed to house in isolation the 
rodent. The proposed nebulizer system will be integrated into the Albira Si micro-
PET/SPECT/CT imaging unit and it will help carry out translational imaging studies of novel 
PET radiolabeled drugs in small animal models of lung disease, such as lung cancer. The 
nebulizer system will be integrated and characterized for activity median aerodynamic diameter 
(AMAD) particle size distribution, aerosol mass distribution, nebulizer triggering using the 
 2 
respiratory cycle, drug and activity pulmonary distribution, and inhalation fraction and particle 
distribution in a normal and diseased rodent’s lung model.   
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NOMENCLATURE  
 
PET  Positron Emission Tomography 
SPECT Single-Photon Emission Computed Tomography 
CT  Computed Tomography 
NP  Nanoparticle 
MPPD  Multiple-Path Particle Dosimetry Model 
IRV   Inspiratory Reserve Volume 
IC  Inspiratory Capacity 
VC  Vital Capacity 
FRC   Functional Residual Capacity 
ERV  Expiratory Reserve Volume 
RV  Residual Volume 
TLC   Total Lung Capacity 
SLC  Solute Carrier (transporter) 
ABC  ATP-Binding Cassette (transporter) 
FRC  Functional Residual Capacity 
GSD  Geometric Standard Deviation 
MMAD  Mass Median Aerodynamic Diameter 
TNF-  Tumor Necrosis Factor Alpha 
18FDG  Fludeoxyglucose (18F) 
  
 5 
CHAPTER I 
INTRODUCTION 
 
Overview 
In vivo imaging is an important tool for preclinical studies of lung function and disease. 
The widespread availability of multimodal animal imaging systems and the rapid rate of 
improvement of diagnostic contrast agents have allowed researchers to noninvasively study lung 
function and pulmonary disorders [1]. There are several imaging modalities used in molecular 
imaging, these are planar x-ray, computerized tomography (CT), magnetic resonance imaging 
(MRI), single photon emission tomography (SPECT), positron emission tomography (PET/CT), 
and bioluminescence [2-4]. All these modalities have their advantages and limitations. Using any 
one of the above imaging modalities it is possible to diagnose, track, and quantify biological 
processes over time. The use of bioluminescence, fluorescence, planar x-ray, x-ray computed 
tomography, magnetic resonance imaging, and nuclear imaging modalities (positron emission 
tomography and single photon emission computed tomography) for the study of lung function 
and pulmonary disorders have been employed in the preclinical setting [5].  However, the 
diagnosis and therapy of lung diseases continuous to be problematic [6-10]. The direct delivery 
of drugs to the lungs is a difficult task that requires the merging of engineering principles in 
aerosol sciences and molecular imaging, including the sustained drug release after inhalation  
[11-15].  
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Merit in Nebulizer Therapy 
Therapies for lung diseases have improved with the development of new highly efficient 
nebulizers that can produce quasi-monodisperse aerosols capable of penetrating the deepest 
regions of the lung [15]. However, the use and reporting of nebulizers is often inconsistent and 
many research studies are irreproducible. Therefore, the standardization of the these devices 
provides researchers the capacity to reproduce studies and duplicate the consistent delivery of 
aerosols to patients [16]. Furthermore, with the advent of active biological nanoparticles as 
drugs, this delivery method is being further investigated to characterize the delivery, 
pharmacokinetics, pharmacodynamics, and overall safety and efficacy of nanoparticles in the 
form of aerosols [17, 18]. However, the study of these aerosol and nanoparticle based drugs 
requires that preclinical animal models be used to assess their safety and efficacy as per FDA 
guidelines. FDA regulates nanotechnology products under existing statutory authorities, in 
accordance with the specific legal standards applicable to each type of product under its 
jurisdiction [19]. We consider the current framework for safety assessment sufficiently robust 
and flexible to be appropriate for a variety of materials, including nanomaterials. FDA maintains 
a product-focused, science-based regulatory policy. Technical assessments will be product-
specific, taking into account the effects of nanomaterials in the particular biological and 
mechanical context of each product and its intended use” [19]. One product, Aurimune (CYT-
6091) by CytImmune Sciences, Inc utilizes colloidal gold and is approved for Phase II 
Preclinical studies for solid tumors using TNF- targeting mechanism [20, 21]. The proposed 
system will help develop translational physiologically based pharmacokinetic models of 
radiolabeled, functionalized gold nanoparticle aerosols inhaled by animal models of disease, 
which in turn can help develop therapy strategies for those in humans.  
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Theory & Existing Work 
This research is comprised of several areas of design and experimentation. These areas 
will be explored to develop a methodology that will assist in providing consistency in the results 
of research. There are two areas of interest: therapeutic pulmonary delivery in rodents and the 
behavior of aerosols in the lungs. 
 
The Vibrating Mesh Atomizer 
This device consists of an annular piezoelectric element that surrounds and contacts the 
mesh. The mesh consists of thousands of holes possessing a conical structure. The larger cross-
section of this conical structure faces the fluid supply for loading. As the piezoelectric element 
activates, it produces a vibration in the mesh that deforms into the fluid supply thus ejecting a 
population of fluid particles on the opposite side. “They have silent operation, short treatment 
times, increased output efficiency, and minimal residual volume. Advantages of mesh nebulizers 
include consistent and improved aerosol generation efficiency, a predominantly ne-particle 
fraction reaching into the peripheral lung, low residual volume, and the ability to nebulize in low 
drug volumes. The size of the pore, the aerosol chamber, and the reservoir, as well as the output 
rate of mesh nebulizers, can be adjusted for different drugs to optimize aerosol drug delivery to 
patients. Mesh nebulizers are more efficient than jet nebulizers and can provide higher drug 
doses to patients. Although human studies with mesh nebulizers are limited, in vitro studies 
demonstrated approximately 2-3 times higher lung deposition with mesh nebulizers when 
compared to jet nebulizers” [22-25]. It is important to consider, though, that the aerosol output 
rate and inhaled fraction will be largely influenced by drug formulations. That is, the 
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performance of these vibrating mesh nebulizers can be hindered by suspensions with a high 
surface tension. In addition, reports exist regarding the blockage of the mesh perforations [26]. 
 
Aerosol Characterization 
Several characterization techniques and attributes exist for a thorough depiction of an 
aerosol and its predicted behavior. One of the key characteristics is known as aerodynamic 
diameter. It is defined as the equivalent diameter of a spherical particle with specific gravity unit 
density but the same settling velocity as the particle under scrutiny. By formulating this attribute, 
one can account for the particle aspect ratio, shape, and size of an individual particle. Since 
aerosols are the sum combination of a large population of particles, the population is described 
using the mass median aerodynamic diameter expressed using geometric standard deviation. The 
geometric standard deviation threshold between mono and poly-dispersed particles is taken to be 
1.0 - 1.2 where particle populations above this threshold are considered poly-dispersed. 
 
Humans vs Mice 
Inhalation is the most significant exposure route for airborne nanoparticles [27]. In 
mammals, the respiratory system can be partitioned into several regions: extra 
thoracic/nasopharyngeal region (nose, mouth, pharynx, larynx), tracheobronchial region (trachea 
to terminal bronchioles: main bronchus, lobar bronchus, segmental bronchus, sub-segmental 
bronchus, conducting bronchiole), and the pulmonary/alveolar region (respiratory bronchiole, 
alveolar duct, alveolar sac, alveolus). A descent into the lungs instigates several trends: an 
increase in the generation of branching, total cross-sectional area, and the residence time in the 
airway; a decrease in the diameter and length of the airway, velocity of fluid in the airway. The 
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relationship that exists between these trends is as follows: the length/diameter decrease and 
branching number increase intuitively elicits a reduction in velocity and increase in residence 
time. These trends distinctly characterize each airway in the lungs thus aerosol particle 
deposition and subsequent deposition mechanisms are also distinct per location in the lung.  
 
 
Figure 1. Comparison of the human (right) and mice (left) lung. Adapted from [28]. 
 
There are many important considerations regarding the differences between human and 
murine lungs  [29-31]. The total lung capacity (TLC) of the mouse is about 1 ml compared to 
6,000 ml of a human. Both humans and mice have 5 lobes distributed between both lungs 
however the left lung in mice is composed of a single lobe. The mouse lung parenchyma 
occupies 18% of the total lung compared to that of 12% for a human. The alveoli of the mouse 
lung have a mean linear intercept of 80 μm compared to that of 210 μm for a human thus they 
are significantly smaller. The blood-gas barrier thickness in the mouse is 0.32 μm compared to 
that of 0.62 μm for a human, which might have important implications for gas exchange, 
parenchymal lung mechanics, and nanoparticle translocation. Fewer respiratory bronchioles and 
airway generations (13–17 generations) oppose the more numerous (17–21 generations) of the 
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human lung. The lungs of each species also differ in symmetry: a monopodial branching pattern 
for mice in contrast to a dichotomous branching pattern for humans. Mice also possess a 
relatively large airway lumen compared to humans [32]. The relatively large size of the lumen in 
mice is likely in place to accommodate air resistivity induced by the rapid respiratory rate (250 – 
350 bpm) required to maintain body temperature [31]. The distribution of submucosal glands is 
different than that seen in humans, present only in the trachea [33]. Lastly, mice tend to have a 
large number of Clara cells [30]. These are morphologically distinct cells that have identified 
importance in anatomical fortification against environmental exposures [36].  In summary, there 
a greater number of differences between the lungs of these species and not all have been detailed 
here. In addition, not only do geometrical differences exist between human and murine lungs, but 
also pathological, physiological, and histological differences as well. The symmetry and size of 
the branching in the lungs will comprise most geometrical differences. These geometrical 
differences and some physiological differences will affect the deposition of aerosols in the lungs 
of each species. The more complex pathological, physiological, and histological differences will 
affect the nature of tumor formation and response to aerosolized nanoparticles in both species 
which may be an important consideration for therapeutic treatment. With xenografting, genetic 
lesions of human lung cancer have been introduced into murine pulmonary tissue to yield lung 
tumors with similar characteristics to those found in humans. In addition, transgenic models have 
allowed for the assessment of oncogenes in tumor origination and development by focusing their 
expression in a subset of lung epithelial cells [5, 34]. The superiority of xenograft, transgenic, 
syngeneic (limited to Lewis lung carcinoma model), and spontaneous tumor models is debatable; 
however, the use of these models has provided a significant advancements in preclinical studies 
in spite of lack of reliability [35]. Murine models possess many advantages, though, to include 
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human genome similarity, proven successful validation of drug target and dosage schemes, cost-
effectiveness and reproducibility, and large–scale phenotyping [36]. 
 
Nanoparticle Synthesis, Radiolabeling, Functionalization, and Translocation 
 Several methods exist for synthesizing gold NPs. At the most basic level, they are 
produced via the reduction of chloroauric acid H[AuCl4]. The Turkevich method is the simplest 
method available and produces gold nanoparticles suspended in water that are around 10-20 nm 
with the normally desired spherical shape and monodispersity. Production of larger particles may 
not yield these desirable characteristics. The Brust method is used to produce gold nanoparticles 
in organic liquids that are not miscible with water that will be in the 2 – 6 nm range. The Martin 
method using a NaBH4 reducing agent and produces nanoparticles in the 3.2 – 5.2 nm range 
which are comparable to those produced using the Brust method. Sonolysis is another method 
that utilizes ultrasound in the presence of chlorauric acid and glucose to form 30 – 50 nm 
nanoribbons.  Spherical nanoparticles can be synthesized using this technique by substituting 
glucose with cyclodextrin. Many colloidal nanoparticle synthesis methods have been 
documented and characterized [44]. Radiolabeled gold nanoparticles can be created by using 
198Au for the nanoparticle synthesis. This isotope is a beta emitter with a range in tissue of about 
11 mm and half-life of 2.7 days. It is also speculated that these gold nanoparticles can be 
synthesized in such a way that they can contain a variety of radioactive isotopes. This serves the 
purpose of flexibility in treatments based on the properties of the isotope: half-life, decay mode, 
decay emission range, etc. Nanoparticle deposition and fate appears understood in a variety of 
scenarios upon a variety of criteria [28]. PEGylation has emerged as a strategy to enhance 
solubility of hydrophobic drugs, prolong circulation time, minimize non-specific uptake, and 
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allow for specific tumor-targeting through the enhanced permeability and retention effect [46]. 
The process consists of coating the nanoparticle with polyethylene glycol. Nanoparticle retention 
is thus extended due to prolonged circulation time. This extension in retention is achieved by 
mitigating the aggregation of nanoparticles in organs and phagocytosis by the reticuloendothelial 
system due to the inherent response toward PEG. This response is achieved by passivating the 
nanoparticle surface so as to conceal the surface reactivity of the nanoparticle. The difference in 
response has been shown between PEGylated and non-PEGylated nanoparticles [47]. An 
excellent article has been published that is very similar to the objective of this study [48]. 
However, the strategy outlined in this study did not include PEGylation or other 
functionalization strategies. Attaching targeting moieties on PEGylated nanoparticles further 
enhances their targeting of tumors [49-51]. This has been proven in several studies. Glucose is a 
common SLC transport system of which there are over 400 members. Glucose is actually the 
transport system of FDG [53]. Maltodextrin is similar to dextrose (glucose) in absorption 
properties however some studies have reported possible elevated absorption rates when 
comparing glucose and maltodextrin diets [54]. This projection of elevated absorption rates 
makes maltodextrin a more attractive candidate as a transport system. In summary, it is intended 
the nanoparticles 
 
Clearance Mechanisms 
Following deposition, the presence of particles is portrayed in two regards: retention and 
clearance. Retention, as the name suggests, is the tendency of particles to remain in pulmonary 
airways. Retention is dependent upon the particle physiochemical properties, the location of their 
deposition, and the clearance mechanism involved. Contrary to retention, clearance is the 
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anatomical tendency to remove undesirable particles from the lungs of which there are multiple 
mechanisms. Clearance mechanisms are important to mention because it may explain the 
translocation behavior of the nanoparticles following the aerosol deposition in the lungs. 
 
Mucociliary Escalator 
For the tracheobronchial region, the dominant clearance mechanism is achieved via 
mucociliary transport consisting of continuous, rhythmic motion of cilia on the bronchial wall 
epithelium. This motion transports contaminant particles upon viscous capture sustained by the 
mucus composed of the gel and periciliary/sol layers produced by goblet cells that lines the 
tracheobronchial region. This phenomenon is common known as the mucociliary escalator. 
Particles captured in the mucus along the airway are propelled toward the pharynx where they 
can be ingested and disposed of in the gastrointestinal tract. The duration of obligatory removal 
of particles using this clearance mechanism is on the order of hours, even less if the particles are 
administered at a low dosage and prove to be irritants, and possibly more if administered in high 
dosages. 
 
Alveolar Macrophages 
Unlike the lung airways, the alveolar regions of the lung are incapable of mucociliary 
transport because their sole function is to provide gas exchange with the bloodstream and 
pulmonary arteries. The clearance mechanism in this region is characterized by alveolar 
macrophages that capture particles and translocate them to the mucociliary escalator, lymphatic 
or venous/circulatory system. The destination of translocation is determined by the solubility of 
captured particles. Soluble substances can permeate the alveolar membrane where they are 
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translocated via the venous system. It is hypothesized that nanoparticles will qualify as soluble 
particle and will thus appear in the venous system. Insoluble substances are likely to be 
transferred to the lymphatic system and the duration of obligatory removal of these particles is 
on the order of months to years. Issues arise if clearance mechanisms are incapacitated. For 
instance, pulmonary fibrosis will occur in the case of prolonged residence of fibro-genic dusts 
because the alveolar macrophage capture mechanism is impaired by those substances.  
Particle translocation was reported using 20 nm iridium nanoparticles from the lung surface into 
pulmonary tissue such that they might be subject to lymphatic drainage and venous incidence 
thus suggesting migration to secondary organs. Some particle translocation resulting in a venous 
presence however small was also reported in a study using TiO2 nanoparticles. The lymphatic 
drainage was not assessed in this study [56, 57]. While a small number of nanoparticles were 
also reported for the iridium translocation (10% of those administered across the secondary 
organs, skeleton, and soft tissue [58]), it can be argued that the method of administration and 
functionalization type would affect this translocation significantly. For instance, TiO2 aerosols 
are generated from nanoparticles that wholly form a powder that is used for delivery. This 
method is in contrast to the delivery method proposed here where Au-NPs are suspended in a 
fluid solution that is the delivery agent to be aerosolized. The functionalization technique, if any, 
used for the iridium particles is not known [59].  
 
Models  
 Using experimental data from research, several models have been developed to model 
deposition to include the Human Respiratory Tract Model from the International Commission on 
Radiological Protection (ICRP) and the National Council on Radiation Protection and 
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Measurement (NCRP). The deposition curves from these models are similar except for 
discrepancies in the ultrafine particle range < 1-2 pm [63]. A java-based application known as 
MPPD or Multiple-Path Particle Dosimetry Model performs calculations to yield an extensive 
amount of information regarding deposition influenced by parameters discussed previously using 
the HRTM models as well as characterized murine models [64].  
Objectives 
The objective of this research is to determine the optimal method for generation and 
pulmonary delivery of an aerosol that is easy and consistent. One of the first steps for 
optimization in rodent preclinical trials is designing the first tailored system for the pulmonary 
delivery of aerosols. Considerations to be taken in the design of this device are material 
composition, geometry, components and systematic relationships, and qualitative efficacy of the 
design. This optimization is intended to assist in experiments that will utilize nanoparticle 
aerosols as contrast agents for single or multi-modal imaging or therapeutic pulmonary delivery 
of radiolabeled nanoparticles to cancer sites for mitigation of metastasis. This document will 
detail the design considerations and results of a synthesized device as well as some specific 
procedures and methodologies for use of the device in select applications. However, the intent is 
not to limit the utilization of the device to these select applications. Rather, the future hopes it 
will be used more generally by revising and adapting these methodologies for any selection of 
applications. 
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CHAPTER II 
DEVICE DESIGN AND FEATURES 
 
Overview 
 The proposed therapeutic device possesses several features to be noted shortly. These 
features can be seen on the device in Figure 2 and the merit of these features and design 
considerations will be elaborated upon in the succeeding sections. 
 
Figure 2. This figure provides a several pictures of the device with annotations. 
 
The therapeutic device is designed with specific considerations for use within the 
AlbiraSi preclinical imaging machine. 
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Bruker AlbiraSi  
 The AlbiraSi is a Full Field of View multimodal PET, SPECT, CT system of high 
performance and MRI compatible. A diagram of the AlbiraSi is provided in Figure 3. 
 
 
Figure 3. This figure provides a detailed diagram of the Albira with included features. 
 
“To better understand the progression and treatment of diseases, you can use Albira's PET, 
SPECT and CT imaging for quantitative 3D tomographic imaging of radiotracers, bone, and soft 
tissue.  Below are just a few of the applications of the Albira system that can provide deep 
insight into the underlying mechanisms of diseases and the effectiveness of new therapeutics: 
 Pharmacokinetics 
 Pharmacodynamics 
 ADME 
 Protein expression 
 Metabolic studies 
 Gene expression 
 Toxicology 
 Perfusion studies” 
 
Some of the technical specifications of the AlbiraSi are provided in Appendix A. The therapeutic 
device will be managed in the “Animal Management Chamber” and then inserted into the 
detection chamber for imaging.    
 
Integration 
Below are figures that illustrate the integration of the system with the complete assembly in the 
Albira Si.  
 
Figure 4. This figure shows the assembly of the device with vacuum and anesthesia lines 
connected in the rear and the AeroGen Pro mounted on top. This figure provides a 
detailed diagram of the device integrated into the Albira. 
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Atomizer 
There is a wide variety of methods used to produce aerosols. The proposed design for this 
research assumes a piezoelectric mesh atomizer which qualifies as an ultrasonic vibrating mesh 
small-volume nebulizer. The device features the AeroGen Pro which contains a vibrating piezo-
electric palladium mesh. “The central aperture plate is just 5mm in diameter and is perforated 
with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the 
optimum particle size for deep lung penetration.”  
 
Figure 5. This figure provides a detailed diagram of the AeroGen Pro with included features. 
This figure lightly illustrates the aerosol dispersion behavior of the atomizer. 
 
AeroGen claims a MMAD of 1-5 µm for this device and the AeroGen Pro used in the 
design was calibrated by AeroGen to have a MMAD of 3.7 µm. A more detailed view of the 
action of the atomizer is shown in Figure 5. The deposition efficiency comparison between the 
AeroGen Pro and traditional small volume nebulizers is illustrated in Figure 6. It can be seen 
from the graphic that the deposition in the lung is more ubiquitous and penetrates deeper for the 
 3 
AeroGen Pro than for that of traditional SVN’s. AeroGen claims that it is capable of producing 
lung deposition of 17% compared to a standard SVN with 3% lung deposition. 
 
 
 
Figure 6. This figure illustrates the efficacy of deposition by the AeroGen Pro compared to 
traditional SVN’s in the human lung. 
 
Anesthesia System 
The device features an anesthesia supply connected via the two input leads on the rear end of the 
device. This supply will feature a variable isoflurane-oxygen mixture. The isoflurane mixture 
will also serve as a mechanism to push the aerosol toward the nose of the specimen and to the 
vacuum. Figure 7 depicts the anesthesia system that links to the device via the leads mentioned 
earlier.                                            
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Figure 7. This figure illustrates the efficacy of deposition by the AeroGen Pro compared to 
traditional SVN’s in the human lung. 
 
Mixing Chamber 
The mixing chamber of the device took significant consideration in the design of the 
geometry. Intuition mandated a funnel design that would attempt to reduce deposition, due to 
geometrically induced turbulence, of the aerosol on the walls of the mixing chamber. The origin 
of this turbulence would stem from the “hard-edge” geometry of a straight cylinder. The 
anesthesia system features two ports at the rear end of the device designed to “push” the aerosol 
through to the other end of the mixing chamber. Originally, these two ports consisted of an entire 
annulus with integrated blades intended to focus the aerosol to the other end of the mixing 
chamber. However, due to complications with the 3D printing process, the blades and annulus 
were abandoned. From Figure 5, it can be seen that at even a close distance from the atomizer, 
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the aerosol features homogeneity in terms of mist velocity and spatial particle distribution. In 
addition, and in contrast with jet atomizers, the generated particles seem to be less prone to 
coalescence and the consequent polydispersity.  
 
Vacuum Exhaust System 
The device features a vacuum exhaust system that removes the excess aerosol from the 
mixing chamber. In addition, the vacuum exhaust regulates the flow of the aerosol to consistently 
pass in front of the nose of the rodent for sustained dosage. There are multiple outlets for this 
vacuum system which are labeled in Figure 4. This feature is a key element in maintaining 
isolation of the specimen from radioactive contamination. In the event the aerosol leaks to the 
housing chamber with the rodent bed, the vacuum system will remove the impurities from this 
region though the outlets. 
 
Figure 8. This figure portrays the vacuum system used during experimentation. 
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Physiological Monitoring  
 The BIOPAC physiological monitoring system is a feature of the Albira Si. This feature 
will play a large role in characterizing the breathing pattern of the rodent specimen. It consists of 
an air-filled, foam-like device that can expand and contract under the pressure of the body of the 
mouse. The pressure changes inside the device will provide readings that can be represented 
graphically.  
 
 Figure 9. This figure portrays the BIOPAC respiratory gating detector 
 
Containment & Isolation System 
 The containment/isolation system of the therapeutic device consists of a cylindrical 
acrylic exterior which should be airtight and capable of displacing all radioactive aerosols from 
the region. Failure to maintain isolation would result contamination of the region surrounding the 
rodent specimen thereby rendering imaging by the Albira Si ineffective and potentially useless.  
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General 
The device is made entirely from 3D printed VeroWhite Polyjet material. The properties 
of this material are detailed in Figure 10.  
 
Figure 10. This figure details the properties of the VeroWhite polyjet 3D printing material. 
 
This material offers great resistance to fluid permeation and offers some of the highest 
resolution/surface finish of other 3D printing materials. The features are important considering 
this device is to be used with radioactive fluids and the device must not harbor any residual 
contamination after use. Another key feature of the device is the internalization of the airway 
channels for both the vacuum and anesthesia systems. This is a feature of both function and 
convenience. By internalizing the channels, the anesthesia can be more effectively directed to the 
mixing chamber to mix with the aerosolized nanoparticle solution. The device also features two 
cap inserts that can be removed to more effectively clean the vacuum channels.  
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CHAPTER III 
METHODOLOGY 
 
Fluid Dynamics 
Currently, no easy simulation techniques exist to model aerosols (several advanced 
methods do exist for this modeling: OpenFOAM, ANSYS CFX, FLUENT) [65, 66] in the 
complex environment proposed here. As a result, it is difficult to model the behavior of the 
aerosol as it propagates through the device without extensive knowledge of the nature of aerosols 
and the physics that govern their behavior. Consequently, the CFD modeling of the device has 
been abandoned for now in spite of the valuable information it may provide regarding the 
internal behavior of the fluid mixture. Fortunately, this might be less of a concern at the moment 
if desirable results are obtained in actual experiments. Regardless, “accurate and reliable models 
for simulating transport, deposition, coagulation, and dispersion of nanoparticles and their 
aggregates are needed for the development of design tools for technological nanoparticle 
applications” [67]. 
 
MPPD Calculations 
MPPD calculations were made for both the human and murine species in conjunction 
with the characterization of the device which were referenced for several determinations made in 
the results section.  
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Figure 11. This figure illustrates the relationships for aerosol respiratory deposition in mice. 
 
 
Figure 12. This figure illustrates the relationships for aerosol respiratory deposition in humans. 
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System Integration & Characterization 
Due to lack of required qualifications, the exact procedures of the initial trial were 
conducted by my advisor and accompanying graduate students. As a result, the exact 
methodology for obtaining the results of this trial will not be detailed thoroughly. The research 
conducted here is intended to explicate the performance of the device first. The system was 
integrated and tested in vivo using mice models. The experiment was conducted via inhaled 
administration of .5 mL of FDG. Appropriate qualitative and quantitative characterizations were 
made regarding the atomizer, anesthesia system, vacuum exhaust system, isolation system, and 
physiological monitoring/data collection. The anesthesia system was controlled by and therefore 
characterized using the system illustrated by Figure 7. The isoflurane-oxygen ratio could be 
adjusted at any point using this system. The vacuum exhaust system depicted in Figure 8 allowed 
for the characterization of the vacuum pressure required for the removal of residual aerosol. 
The isolation system was characterized using the images formed by the Albira Si imaging 
reconstruction. The images were assessed for radioactivity denoted by color. If any color was 
visible around the animal bed, the isolation system would be deemed malfunctioned because  
contamination would have permeated the animal housing chamber. The animal physiology 
monitoring was conducted using the BIOPAC monitoring system illustrated in Figure 9 and the 
specimen physiology was characterized thusly. The data collection produced from this 
monitoring provides insight into the respiratory pattern that is manifested in response to the 
anesthesia and otherwise.  
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Figure 13. This figure details the breathing pattern of the mouse used in experimentation. 
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CHAPTER IV 
RESULTS AND DISCUSSION 
 
Upon the first trial of the therapeutic device and its integration in the Albira Si, a number 
of significant findings were educed and are detailed here. First, the vacuum exhaust must be 
sufficient enough to extract the aerosol at a rate that prevents the mouse from suffocating from a 
dense concentration of aerosolized FDG, although, the exact magnitude of this exhaust pressure 
has yet to be characterized. The MMAD of the aerosol generated by the AeroGen Pro is 3.7 µm. 
This particle size is much too large for distal deposition in murine specimens. Ideal particle size 
is around 0.01 µm as can be seen from MPPD models. It can be seen from Figure 14 that the 
activity inhaled by the murine specimen was incredibly low and particle deposition seemed only 
to occur in the nose. One speculation does exist in consideration of both the MPPD models and 
the features of the device itself. Some experiments reported sufficient deposition using the 
Aerogen Pro and not with roughly the same MMAD [68-70]. This proposes the idea that the 
vacuum system removes those smaller particles that would yield the desired distal deposition. It 
is important to note, also, that if the particles generated from the AeroGen Pro are, in fact, 
monodisperse, the idea aforementioned can be refuted. Finally, the radioactive tracer substance 
is, in fact, contained within the device so as to prevent contamination in the mouse bed which 
would interfere with PET/CT imaging by the Albira Si. 
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Figure 14. This figure illustrates the distribution of FDG in the device 
 
Figure 15. This figure also illustrates the distribution of FDG in the device at the denoted slice 
locations. 
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CHAPTER V 
CONCLUSION 
 
It is important to consider the long-term use of this device in regard to its current 
fabrication. While the absorption of fluid by the device is not projected to be an issue given the 
material composition, long term use may challenge this projection. If the device does absorb 
radioactive material, this will have serious implications regarding the function and handling of 
the device. The absorption will be evident and obvious in the image reconstruction performed by 
the Albira Si. While the device is currently a prototype, this consideration must be stated so that 
better material composition options can be explored to include those that are completely 
impermeable to fluid and transparent for monitoring of aerosol behavior within the mixing 
chamber. As can be seen in Figure 14, significant condensation occurs internal to the device 
which may affect prolonged use and efficiency. Recovery methods of condensate should be 
explored. Alternatively, a pulsing method for aerosol generation might prove to be a better but 
more difficult implementation. Currently, the Aerogen Pro features a USB controller that can 
adjust the treatment method between a 30 min and 6-hour dose. Ideally, this USB controller 
could be altered for connectivity to a computer and thereby a range of programming possibilities. 
If this is accomplished, two options present themselves. First, the respiratory pattern collected 
from the BIOPAC monitoring system can be analyzed by a computer program to determine the 
optimal point for pulsing of the atomizer. This would mean that in order to changing the pulsing 
pattern, one would need to alter the computer code. A continuous flow of the aerosol would be 
foremost inefficient and to attempt to match the BPM of a normal rodent would fail to account 
for the effect of anesthesia on the specimen and any other potential variability that might occur. 
 15 
However, an even better solution would suggest the real-time evaluation of the respiratory 
pattern and a consequent synchronization of the atomizer pulsing. This would accomplish several 
things: the system would be able to account for changes in the specimen breathing pattern, the 
suffocation endured by the mouse would still be avoided and the vacuum system would only 
require activation upon absolute necessity (or run passively at a much lower vacuum pressure), 
the speculated effects of the vacuum removal of preferred-sized particles would be irrelevant, 
and the amount of aerosol administered would be dramatically reduced thus conserving the 
active substance and reducing the amount of condensate that resides in the mixing chamber. Due 
to the dramatic reduction in breathing rate accomplished by the isoflurane, the body temperature 
of the murine specimen also dramatically decreases. With this consideration, it might also be 
beneficial to explore the implementation of a heated bed to maintain the normal body 
temperature of the specimen. 
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APPENDIX A 
 
ALBIRA SI SPECIFICATIONS 
Full Field Accuracy (FFA) 
FFA offers real, homogeneous sub-millimetric volumetric PET resolution in all three axes in the 
whole field of view, with superior precision in quantification based on: Exclusive continuous 
crystal detectors with new Si PM technology and true depth of interaction 3D precision 
equivalent to 10+ layer pixelated crystal detectors. 
Virtual pixels optimizing very fast, low dose, maximum sensitivity studies and allowing software 
based performance upgrades Proprietary electronics and software with row and column readout, 
enabling advanced depth-of-interaction measurement and correction. 
This patented technology generates an area of optimum resolution up to 10 times larger than 
conventional options.  
 
System Specifications 
 Imaging Modalities: PET, SPECT, CT 
 Core Technologies: Patented continuous crystal technology with Row And Column readout + 
proprietary electronics + HR 3D DOI 
 Unit Size: Single compact footprint 
 Shielding: Fully Shielded 
 Weight: 800 kg 
 Bore Size: 105 
 
Animal Care Monitoring And Control 
 Anesthesia: Fully integrated. Compatible with most common commercial gas systems 
 Animal Handling System: Reliable, easy to use rat and mouse beds; Fully compatible with 
BRUKER MR 
 Physiological Signals: ECG, Respiration, Temperature, And Blood Pressure 
 Temperature Control System: Electrically heated mats for rat And mouse 
 Video Monitoring: Real-time camera 
 Gating Acquisition: Cardiac and Respiratory For PET and SPECT; Dual Gating for PET 
 
Software And Workstation 
 Fully Integrated Albira Suite: ACQUIRER: Image Acquisition, RECONSTRUCTOR: Image 
Reconstruction, MANAGER: Study and Protocol Management, SUPERVISOR: Quality 
Control 
 Image Analysis Software: PMOD (PBAS, PFUS, PKIN MODULES INCLUDED) 
 3D Rendering Software: VOLVIEW (+ PMOD) 
 Workstation: Dedicated Server; All Functionalities on a single system 
 Reconstruction: GPU Based, Scalable To 4 GPUs (PET); CPU Based SPECT and CT 
 Data Storage: 3 * 4TB RAID 5 Configuration; Upgradable on same Workstation 
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PET System 3 Ring 
 Module Architecture: 24 Modules, 8 modules per ring; Patented continous crystal coupled to 
12x12 SiPM; Propietary electronics optimized for HR 3D DoI; 
 Spatial Resolution: Up to 0,7 mm; Guaranteed submilimetric volumetric resolution; FULL 
FIELD ACCURACY: Homogeneous resolution better than 1,2 mm in the whole FoV of 80+ 
mm; 
 Axial FOV: 148 mm 
 Transaxial FOV: 80 mm 
 Sensitivity: 12%; 9% NEMA 
 Average Energy Resolution: 17% 
 Reconstruction Algorithm: MLEM, Ultra fast GPU based 
 Sensitivity: 9% 
 NECR Mouse: Peak: 560 kcps at 35 MBq 
 NECR Rat: Peak: 330 kcps at 43 MBq 
 
PET System 1 Ring 
 Module Architecture: 8 Modules in 1 ring configuration; Patented continous crystal coupled to 
12x12 SiPM; Propietary electronics optimized for HR 3D DoI 
 Spatial Resolution: Up to 0,7 mm[1]; Guaranteed submilimetric volumetric resolution; FULL 
FIELD ACCURACY: Homogeneous resolution better than 1,2 mm in the whole FoV of 80+ 
mm 
 Axial FOV: 46 mm 
 Transaxial FOV: 80 mm 
 Sensitivity: 4,5%; 3% NEMA 
 Average Energy Resolution: 17% 
 Reconstruction Algorithm: MLEM, Ultra fast GPU based 
 NECR Mouse: Peak: 80 kcps at 35 MBq 
 NECR Rat: Peak: 20 kcps at 43 MBq 
 
CT Specifications 
 X RAY ENERGY: 10 – 50 kVp 
 detector: Digital flat panel 2400x2400 pixels 
 SPATIAL RESOLUTION: 90 um 
 MAXIMUM CURRENT: 1 mA 
 FOV: 70x70 mm 
 
SPECT 108 Specifications 
 DETECTOR: Dual head camera system with patented continous CsI(Na) crystal technology 
 SENSITIVITY: 1.800 cps/MBq 
 ENERGY RESOLUTION: 0,18 
 ENERGY RANGE: 30 – 400 keV 
 VARIABLE FOV: 25 – 120 mm 
 SPATIAL RESOLUTION: 0.5 mm 
 COLLIMATORS: A.General Purpose; B. High Energy; C. High Resolution; D. Multipinhole; 
 RECONSTRUCTION: OSEM, Fast Reconstruction 
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Best in class specifications under real lab conditions  
 Resolution up to 0.7 mm 
 Sensitivity of 12% 
 NEMA NECR peak rates: mouse 560 kcps, rat 330 kcps 
 Unprecedented quantification and dynamic study performance 
 Large axial FOV of 148 mm 
 Cardiac and respiratory gating 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
